You are here

Data Presented at the North American Cystic Fibrosis Conference Demonstrate Our Important Progress


November 3, 2017

Each year, scientists, clinicians, and cystic fibrosis caregivers from around the world come together at the North American Cystic Fibrosis Conference (NACFC) to discuss and share ideas on the latest advances in CF care, research, drug development and ways to improve the health and quality of life for people with CF. Having developed the first medicines that treat the underlying cause of CF - this is an exciting event for Vertex and one we look forward to every year. This year we presented data from across our portfolio of cystic fibrosis medicines, and medicines in development, that demonstrate the important progress we’re making toward our goal of helping all people with CF. We also presented data from our phase 3 studies of the investigational tezacaftor/ivacaftor combination treatment as published in the New England Journal of Medicine.

It’s also an important time for us to connect with the CF community. Timed with this year’s event, we announced a new $750,000 Independent Research Innovation Award to support the work of the next generation of CF researchers. This new award expands the existing CF Research Innovation Awards (RIA) program and opens the program to applicants outside of the United States. Funding for the CF RIA program now totals nearly $10 million over the next five years. This program is part of Vertex’s recently announced 10-year, $500 million corporate giving commitment.

About Our Data Presented at NACFC

Vertex presented a breadth of research data, which demonstrate important progress toward our goal of helping all people with CF. Key presentations highlighted the acute and long-term benefits of CFTR modulation, including data from an ongoing extension study of ORKAMBI® (lumacaftor/ivacaftor). New data was also presented on KALYDECO® (ivacaftor) and our third potential CF medicine tezacaftor/ivacaftor in triple combination regimens.